Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
CMTX
MCID: XLN110
MIFTS: 43

X-Linked Charcot-Marie-Tooth Disease (CMTX)

Categories: Ear diseases, Eye diseases, Fetal diseases, Genetic diseases, Mental diseases, Metabolic diseases, Muscle diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for X-Linked Charcot-Marie-Tooth Disease

About this section

MalaCards integrated aliases for X-Linked Charcot-Marie-Tooth Disease:

Name: X-Linked Charcot-Marie-Tooth Disease 52 58
X-Linked Hereditary Motor and Sensory Neuropathy 52 58 29 6
Cmtx 52 58
Charcot-Marie-Tooth Disease, X-Linked, 1 71
Charcot-Marie-Tooth, X-Linked 6

Characteristics:

Orphanet epidemiological data:

58
x-linked charcot-marie-tooth disease
Inheritance: X-linked dominant,X-linked recessive;

Classifications:

MalaCards categories:
Global: Rare diseases Fetal diseases Genetic diseases Metabolic diseases
Anatomical: Neuronal diseases Ear diseases Eye diseases Muscle diseases Mental diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 58  
Rare neurological diseases
Rare otorhinolaryngological diseases
Developmental anomalies during embryogenesis


External Ids:

ICD10 via Orphanet 33 G60.0
Orphanet 58 ORPHA64747
UMLS 71 C0393808
Sources

Summaries for X-Linked Charcot-Marie-Tooth Disease

About this section
NIH Rare Diseases : 52 The following summary is from Orphanet , a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 64747 Definition A disorder that belongs to the genetically heterogeneous group of CMT peripheral sensorimotor polyneuropathy diseases. Clinical description CMTX1 is characterized by a slowly progressive course: muscle wasting and weakness of distal limb muscles mainly involving the feet, legs and hands (particularly the thenar eminence), with proximal muscle weakness occurring in severe cases; distal sensory loss; loss of deep tendon reflexes; pes cavus and more rarely scoliosis . Rare instances of transient central nervous system (CNS) dysfunction have been described, with dysarthria , dysphagia , weakness, ataxia , and even aphasia and somnolence. All forms of CMTX are rare and are characterized by intellectual deficit (CMTX2, CMTX4), spastic paraplegia (CMTX3), hearing loss (CMTX4, CMTX5, rarely CMTX1), and optic atrophy (CMTX5). Etiology CMTX1 is associated with mutations in the GJB1 gene (Xq13.1), encoding connexin 32 (Cx32). Cx32 forms gap-junctions in non-compact myelin produced by myelinating Schwann cells . Cx32 is also expressed in oligodendrocytes, explaining the potential CNS involvement. CMTX5 is associated with mutations in the phosphoribosylpyrophosphate synthetase 1 gene (PRPS1 ). CMTX1 is transmitted as an X-linked dominant trait and males are more severely affected than females, whereas the other CMTX types are X-linked recessive and female carriers are usually unaffected. Diagnostic methods Diagnosis is based on family and personal history, clinical examination, nerve conduction studies (NCS), and DNA testing (for CMTX1). NCS show a sensorimotor polyneuropathy with decreased conduction velocities in males (usually in the intermediate range of 30-45 m/s in upper limb motor nerves) and mildly decreased or even normal velocities in females. In contrast with other CMT types, conduction slowing is frequently nonhomogeneous, with temporal dispersion and sometimes conduction blocks, and the median nerve being more severely affected than the ulnar nerve. Nerve biopsy reveals prominent axonal changes, in spite of nerve conduction slowing, with evidence of ultrastructural abnormalities in the paranodal regions. Auditory evoked potentials usually reveal abnormalities of central waves in the brainstem, consistent with frequent subclinical brain involvement in CMTX1. Differential diagnosis Differential diagnosis includes other CMT types and acquired dysimmune neuropathies such as chronic inflammatory demyelinating polyradiculoneuropathy (see these terms). Antenatal diagnosis Prenatal diagnosis is possible for CMTX1 when the mutation is known. Genetic counseling As an X-linked dominant trait, there is no male-to-male transmission; female carriers are usually mildly affected and have a 50% risk of transmitting the disease to their offspring. Management and treatment There is no drug treatment available. Rehabilitation therapy and surgical treatment of skeletal deformities are the only options. Prognosis CMTX1 is moderately severe for affected males, who may loose ambulation capacity later in life. Visit the Orphanet disease page for more resources.

MalaCards based summary : X-Linked Charcot-Marie-Tooth Disease, also known as x-linked hereditary motor and sensory neuropathy, is related to charcot-marie-tooth disease, x-linked recessive, 5 and charcot-marie-tooth disease, x-linked recessive, 3, and has symptoms including tremor, paraparesis and numbness. An important gene associated with X-Linked Charcot-Marie-Tooth Disease is GJB1 (Gap Junction Protein Beta 1), and among its related pathways/superpathways are Gap junction trafficking and Oligomerization of connexins into connexons. The drugs Dexamethasone acetate and Methotrexate have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and eye, and related phenotypes are Decreased viability and Decreased viability

Sources

Related Diseases for X-Linked Charcot-Marie-Tooth Disease

About this section

Diseases in the Charcot-Marie-Tooth Disease, X-Linked Dominant, 1 family:

Charcot-Marie-Tooth Disease, X-Linked Dominant, 6 Charcot-Marie-Tooth Disease, X-Linked Recessive, 2
Charcot-Marie-Tooth Disease, X-Linked Recessive, 3 Charcot-Marie-Tooth Disease, X-Linked Recessive, 5
Charcot-Marie-Tooth Disease X-Linked Recessive 4 X-Linked Charcot-Marie-Tooth Disease

Diseases related to X-Linked Charcot-Marie-Tooth Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Related Disease Score Top Affiliating Genes
1 charcot-marie-tooth disease, x-linked recessive, 5 33.9 PRPS1 GJB1
2 charcot-marie-tooth disease, x-linked recessive, 3 33.5 GJB1 CMTX3
3 charcot-marie-tooth disease x-linked recessive 4 33.4 PRPS1 GJB1
4 charcot-marie-tooth disease, x-linked recessive, 2 33.0 PRPS1 GJB1
5 charcot-marie-tooth disease, x-linked dominant, 6 32.6 PRPS1 PDK3 GJB1
6 tooth disease 31.2 PRPS1 PDK3 GJB1
7 charcot-marie-tooth disease type x 30.5 PRPS1 GJB1
8 charcot-marie-tooth disease 29.4 PRPS1 PDK3 GJB2 GJB1 DLX4 CMTX3
9 charcot-marie-tooth disease, x-linked dominant, 1 12.5
10 charcot-marie-tooth disease, x-linked recessive, 4, with or without cerebellar ataxia 11.8
11 charcot-marie-tooth neuropathy x type 1 11.1
12 neuropathy 11.0
13 peripheral nervous system disease 11.0
14 sensory peripheral neuropathy 10.9
15 hereditary neuropathies 10.8
16 branchiootic syndrome 1 10.8
17 muscular atrophy 10.7
18 charcot-marie-tooth disease, demyelinating, type 1a 10.7
19 sensorineural hearing loss 10.7
20 polyneuropathy 10.7
21 multiple sclerosis 10.6
22 ataxia and polyneuropathy, adult-onset 10.6
23 amyotrophic lateral sclerosis 1 10.5
24 arts syndrome 10.5
25 charcot-marie-tooth disease type 5 10.5
26 lateral sclerosis 10.5
27 axonal neuropathy 10.5
28 dysphagia 10.5
29 tremor 10.5
30 seizures, benign familial neonatal, 1 10.4
31 neuropathy, hereditary, with liability to pressure palsies 10.4
32 pheochromocytoma 10.4
33 3-methylglutaconic aciduria, type iii 10.4
34 deafness, x-linked 1 10.4
35 neuropathy, congenital hypomyelinating, 1, autosomal recessive 10.4
36 slowed nerve conduction velocity, autosomal dominant 10.4
37 mitochondrial dna depletion syndrome 4b 10.4
38 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.4
39 adrenal gland pheochromocytoma 10.4
40 stuttering 10.4
41 hemiplegia 10.4
42 respiratory failure 10.4
43 relapsing-remitting multiple sclerosis 10.4
44 demyelinating disease 10.4
45 central nervous system disease 10.4
46 chronic inflammatory demyelinating polyradiculoneuropathy 10.4
47 demyelinating polyneuropathy 10.4
48 acute disseminated encephalomyelitis 10.4
49 hyperthyroidism 10.4
50 charcot-marie-tooth neuropathy x type 5 10.4

Graphical network of the top 20 diseases related to X-Linked Charcot-Marie-Tooth Disease:



Diseases related to X-Linked Charcot-Marie-Tooth Disease
Sources

Symptoms & Phenotypes for X-Linked Charcot-Marie-Tooth Disease

About this section

UMLS symptoms related to X-Linked Charcot-Marie-Tooth Disease:


tremor, paraparesis, numbness, monoparesis

GenomeRNAi Phenotypes related to X-Linked Charcot-Marie-Tooth Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 8.92 GJB1 PDK3
2 Decreased viability GR00402-S-2 8.92 GJB1 PDK3
Sources

Drugs & Therapeutics for X-Linked Charcot-Marie-Tooth Disease

About this section

Drugs for X-Linked Charcot-Marie-Tooth Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 70)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
2
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
3
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
4
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
5
Daunorubicin Approved Phase 3 20830-81-3 30323
6
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
7
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
8
Ichthammol Approved Phase 3 8029-68-3
9
leucovorin Approved Phase 3 58-05-9 6006 143
10
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
11
Mercaptopurine Approved Phase 3 50-44-2 667490
12
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
13
Ifosfamide Approved Phase 3 3778-73-2 3690
14
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
15
Bortezomib Approved, Investigational Phase 3 179324-69-7 387447 93860
16
Thioguanine Approved Phase 3 154-42-7 2723601
17
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
18
Pegaspargase Approved, Investigational Phase 3 130167-69-0
19
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
20
Etoposide Approved Phase 3 33419-42-0 36462
21
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
22
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
23
Cortisone Experimental Phase 3 53-06-5 222786
24
Emodepside Investigational, Vet_approved Phase 3 155030-63-0
25 Antiemetics Phase 3
26 Hydrocortisone hemisuccinate Phase 3
27 Trace Elements Phase 3
28 Anti-Bacterial Agents Phase 3
29 Immunologic Factors Phase 3
30 HIV Protease Inhibitors Phase 3
31 Alkylating Agents Phase 3
32 Vitamins Phase 3
33 Micronutrients Phase 3
34
protease inhibitors Phase 3
35 Hydrocortisone 17-butyrate 21-propionate Phase 3
36 Podophyllotoxin Phase 3 518-28-5
37 Hydrocortisone-17-butyrate Phase 3
38 Gastrointestinal Agents Phase 3
39 Anti-Inflammatory Agents Phase 3
40
asparaginase Phase 3
41 Vitamin B Complex Phase 3
42
Isophosphamide mustard Phase 3 0
43 Anti-Infective Agents Phase 3
44 Vitamin B9 Phase 3
45 Autonomic Agents Phase 3
46 Nutrients Phase 3
47 Folic Acid Antagonists Phase 3
48 Hormone Antagonists Phase 3
49 Antimitotic Agents Phase 3
50 Dermatologic Agents Phase 3

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy) Active, not recruiting NCT02112916 Phase 3 Bortezomib;Cyclophosphamide;Cytarabine;Daunorubicin;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin;Doxorubicin Hydrochloride;Etoposide;Hydrocortisone Sodium Succinate;Ifosfamide;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Thioguanine;Vincristine;Vincristine Sulfate
2 A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease Types 1 and X Active, not recruiting NCT03124459 Phase 2 ACE-083;Placebo
3 An Open-Label Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) Previously Enrolled in Study A083-02 and in Patients With Charcot-Marie Tooth (CMT) Disease Types 1 and X Previously Enrolled in Study A083-03 Enrolling by invitation NCT03943290 Phase 2 ACE-083
4 Patient Reported Outcomes Measures (PROM) in Carpal Tunnel Therapies in Patients With Inherited Neuropathies Completed NCT02788734

Search NIH Clinical Center for X-Linked Charcot-Marie-Tooth Disease

Sources

Genetic Tests for X-Linked Charcot-Marie-Tooth Disease

About this section

Genetic tests related to X-Linked Charcot-Marie-Tooth Disease:

# Genetic test Affiliating Genes
1 X-Linked Hereditary Motor and Sensory Neuropathy 29 GJB1
Sources

Anatomical Context for X-Linked Charcot-Marie-Tooth Disease

About this section

MalaCards organs/tissues related to X-Linked Charcot-Marie-Tooth Disease:

40
Brain, Testes, Eye, Adrenal Gland
Sources

Publications for X-Linked Charcot-Marie-Tooth Disease

About this section

Articles related to X-Linked Charcot-Marie-Tooth Disease:

(show top 50) (show all 175)
# Title Authors PMID Year
1
Expansion of the phenotypic spectrum of X-linked Charcot-Marie-Tooth (CMT) disease. 61
31987637 2020
2
Evidence for Cognitive Deficits in X-Linked Charcot-Marie-Tooth Disease. 61
31948496 2020
3
A novel GJB1 mutation associated with X-linked Charcot-Marie-Tooth disease in a large Chinese family pedigree. 61
31943912 2020
4
Atypical Pediatric Demyelinating Diseases of the Central Nervous System. 61
31773416 2019
5
Gene replacement therapy after neuropathy onset provides therapeutic benefit in a model of CMT1X. 61
31411673 2019
6
X-linked Charcot-Marie-Tooth Disease Presenting with Stuttering Stroke-like Symptoms. 61
31220874 2019
7
A novel mutation in PRPS1 causes X-linked Charcot-Marie-Tooth disease-5. 61
31434166 2019
8
CNS phenotype in X linked Charcot- Marie-Tooth disease. 61
30518545 2019
9
Three novel mutations in a group of Chinese patients with X-linked Charcot-Marie-Tooth disease. 61
31323543 2019
10
New novel mutations in Brazilian families with X-linked Charcot-Marie-Tooth disease. 61
31119804 2019
11
X-linked Charcot-Marie-Tooth disease type 5 with recurrent weakness after febrile illness. 61
30177296 2019
12
X linked Charcot-Marie-Tooth disease and multiple sclerosis: emerging evidence for an association. 61
30196252 2019
13
A Novel Variant in Non-coding Region of GJB1 Is Associated With X-Linked Charcot-Marie-Tooth Disease Type 1 and Transient CNS Symptoms. 61
31068899 2019
14
Genetic and phenotypic profile of 112 patients with X-linked Charcot-Marie-Tooth disease type 1. 61
29998508 2018
15
Acetylation of C-terminal lysines modulates protein turnover and stability of Connexin-32. 61
30268116 2018
16
A novel AIFM1 mutation in a Chinese family with X-linked Charcot-Marie-Tooth disease type 4. 61
30031633 2018
17
Anaesthesia and orphan diseases: anaesthetic management of a patient with X-linked Charcot-Marie-Tooth disease type 1. 61
29870477 2018
18
Reversible lesions of the corpus callosum with initially restricted diffusion in a series of Caucasian children. 61
29666887 2018
19
[Transient, recurrent, white matter lesions in X-linked Charcot-Marie-Tooth disease with heterozygote mutation of GJB1 gene: case report of a female patient]. 61
29710024 2018
20
An 8-generation family with X-linked Charcot-Marie-Tooth: Confirmation Of the pathogenicity Of a 3' untranslated region mutation in GJB1 and its clinical features. 61
29236290 2018
21
Coexistence of Amyotrophic Lateral Sclerosis in the Proband of an X-Linked Charcot-Marie-Tooth Disease Type 1 Pedigree in China. 61
29629536 2018
22
Intrathecal gene therapy in mouse models expressing CMT1X mutations. 61
29462293 2018
23
Preimplantation genetic diagnosis of X-linked Charcot-Marie-Tooth disease by indirect linkage analysis. 61
28797703 2018
24
The Electrophysiological Features in X-Linked Charcot-Marie-Tooth Disease With Transient Central Nervous System Deficits. 61
30013503 2018
25
Substitution impact of highly conserved arginine residue at position 75 in GJB1 gene in association with X-linked Charcot-Marie-tooth disease: A computational study. 61
29111421 2018
26
A novel missense mutation in AIFM1 results in axonal polyneuropathy and misassembly of OXPHOS complexes. 61
28888069 2017
27
X-linked Charcot-Marie-Tooth disease with GJB1 mutation presenting as acute disseminated encephalomyelitis-like illness: A case report. 61
29245364 2017
28
Charcot-Marie-Tooth Disease 1X Simulating Paraparetic Guillain-Barre Syndrome. 61
29095325 2017
29
Clinical characterization and genetic analysis of Korean patients with X-linked Charcot-Marie-Tooth disease type 1. 61
28448691 2017
30
Cross-sectional analysis of a large cohort with X-linked Charcot-Marie-Tooth disease (CMTX1). 61
28768847 2017
31
Deletion of P2 promoter of GJB1 gene a cause of Charcot-Marie-Tooth disease. 61
28601552 2017
32
Mutations in noncoding regions of GJB1 are a major cause of X-linked CMT. 61
28283593 2017
33
Centrally involved X-linked Charcot-Marie-Tooth disease presenting as a stroke-mimic. 61
28097225 2017
34
Systemic inflammation disrupts oligodendrocyte gap junctions and induces ER stress in a model of CNS manifestations of X-linked Charcot-Marie-Tooth disease. 61
27585976 2016
35
CNS involvement in CMTX1 caused by a novel connexin 32 mutation: a 6-year follow-up in neuroimaging and nerve conduction. 61
27098243 2016
36
A Review of X-linked Charcot-Marie-Tooth Disease. 61
26385972 2016
37
Mutation Analysis of Gap Junction Protein Beta 1 and Genotype-Phenotype Correlation in X-linked Charcot-Marie-Tooth Disease in Chinese Patients. 61
27098783 2016
38
Intrathecal gene therapy rescues a model of demyelinating peripheral neuropathy. 61
27035961 2016
39
Secondary structural analysis of the carboxyl-terminal domain from different connexin isoforms. 61
26542351 2016
40
X-linked Charcot-Marie-Tooth disease type 6 (CMTX6) patients with a p.R158H mutation in the pyruvate dehydrogenase kinase isoenzyme 3 gene. 61
26801680 2016
41
A novel AIFM1 mutation expands the phenotype to an infantile motor neuron disease. 61
26173962 2016
42
Intraneural GJB1 gene delivery improves nerve pathology in a model of X-linked Charcot-Marie-Tooth disease. 61
26010264 2015
43
A start codon CMT1X mutation associated with transient encephalomyelitis causes complete loss of Cx32. 61
25771809 2015
44
GJB1-associated X-linked Charcot-Marie-Tooth disease, a disorder affecting the central and peripheral nervous systems. 61
25370202 2015
45
Connexin: a potential novel target for protecting the central nervous system? 61
26170830 2015
46
A novel mutation in GJB1 (c.212T>G) in a Chinese family with X-linked Charcot-Marie-Tooth disease. 61
25595958 2015
47
Relapsing remitting multiple sclerosis in x-linked charcot-marie-tooth disease with central nervous system involvement. 61
25883816 2015
48
Episodic neurological dysfunction in hereditary peripheral neuropathy. 61
25745327 2015
49
Gene expression profiling studies in regenerating nerves in a mouse model for CMT1X: uninjured Cx32-knockout peripheral nerves display expression profile of injured wild type nerves. 61
25447941 2015
50
Novel familial pathogenic mutation in gap junction protein, beta-1 gene (GJB1) associated with transient neurological deficits in a patient with X-linked Charcot-Marie-Tooth disease. 61
25043634 2014
Sources

Variations for X-Linked Charcot-Marie-Tooth Disease

About this section

ClinVar genetic disease variations for X-Linked Charcot-Marie-Tooth Disease:

6 (show top 50) (show all 77) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 GJB1 NM_000166.6(GJB1):c.259C>G (p.Pro87Ala)SNV Pathogenic 155724 rs587777877 X:70443816-70443816 X:71223966-71223966
2 GJB1 NM_000166.6(GJB1):c.580A>G (p.Met194Val)SNV Pathogenic 155725 rs587777878 X:70444137-70444137 X:71224287-71224287
3 GJB1 NM_000166.6(GJB1):c.77C>T (p.Ser26Leu)SNV Pathogenic 155726 rs587777876 X:70443634-70443634 X:71223784-71223784
4 GJB1 NM_000166.6(GJB1):c.790C>T (p.Arg264Cys)SNV Pathogenic 155727 rs587777879 X:70444347-70444347 X:71224497-71224497
5 GJB1 NM_000166.6(GJB1):c.-103C>TSNV Pathogenic 217166 rs863224971 X:70443099-70443099 X:71223249-71223249
6 GJB1 NM_000166.6(GJB1):c.44G>A (p.Arg15Gln)SNV Pathogenic 217169 rs863224974 X:70443601-70443601 X:71223751-71223751
7 GJB1 NM_000166.6(GJB1):c.224G>A (p.Arg75Gln)SNV Pathogenic 217167 rs863224972 X:70443781-70443781 X:71223931-71223931
8 GJB1 NM_000166.6(GJB1):c.319C>T (p.Arg107Trp)SNV Pathogenic 217168 rs863224973 X:70443876-70443876 X:71224026-71224026
9 GJB1 NM_000166.6(GJB1):c.490C>T (p.Arg164Trp)SNV Pathogenic 217170 rs139643362 X:70444047-70444047 X:71224197-71224197
10 GJB1 NM_000166.6(GJB1):c.424C>T (p.Arg142Trp)SNV Pathogenic 10431 rs104894810 X:70443981-70443981 X:71224131-71224131
11 GJB1 NM_000166.6(GJB1):c.514C>T (p.Pro172Ser)SNV Pathogenic 10432 rs104894811 X:70444071-70444071 X:71224221-71224221
12 GJB1 NM_000166.6(GJB1):c.415G>A (p.Val139Met)SNV Pathogenic 10433 rs104894812 X:70443972-70443972 X:71224122-71224122
13 GJB1 NM_000166.6(GJB1):c.397T>C (p.Trp133Arg)SNV Pathogenic 10434 rs104894813 X:70443954-70443954 X:71224104-71224104
14 GJB1 NM_000166.6(GJB1):c.658C>T (p.Arg220Ter)SNV Pathogenic 10435 rs104894814 X:70444215-70444215 X:71224365-71224365
15 GJB1 NM_000166.6(GJB1):c.89T>A (p.Ile30Asn)SNV Pathogenic 10436 rs104894817 X:70443646-70443646 X:71223796-71223796
16 GJB1 NM_000166.6(GJB1):c.194A>G (p.Tyr65Cys)SNV Pathogenic 10438 rs104894819 X:70443751-70443751 X:71223901-71223901
17 GJB1 NM_000166.6(GJB1):c.37G>T (p.Val13Leu)SNV Pathogenic 10439 rs104894820 X:70443594-70443594 X:71223744-71223744
18 GJB1 GJB1, 1-BP DELdeletion Pathogenic 10440
19 GJB1 NM_000166.6(GJB1):c.283G>A (p.Val95Met)SNV Pathogenic 10441 rs104894821 X:70443840-70443840 X:71223990-71223990
20 GJB1 NM_000166.6(GJB1):c.614A>G (p.Asn205Ser)SNV Pathogenic 10442 rs104894822 X:70444171-70444171 X:71224321-71224321
21 GJB1 GJB1, 367G-TSNV Pathogenic 10443
22 GJB1 GJB1, -528T-GSNV Pathogenic 10445
23 GJB1 NM_000166.6(GJB1):c.164C>T (p.Thr55Ile)SNV Pathogenic 10446 rs104894824 X:70443721-70443721 X:71223871-71223871
24 GJB1 GJB1, 21-BP DUPduplication Pathogenic 10447
25 GJB1 GJB1, 3-BP DEL, 304GAGdeletion Pathogenic 10448
26 GJB1 GJB1, -526G-CSNV Pathogenic 10449
27 GJB1 NM_000166.6(GJB1):c.407T>C (p.Val136Ala)SNV Pathogenic 10451 rs104894826 X:70443964-70443964 X:71224114-71224114
28 GJB1 NM_000166.6(GJB1):c.187G>A (p.Val63Ile)SNV Pathogenic 21081 rs116840818 X:70443744-70443744 X:71223894-71223894
29 GJB1 NM_000166.6(GJB1):c.223C>T (p.Arg75Trp)SNV Pathogenic 21082 rs116840819 X:70443780-70443780 X:71223930-71223930
30 GJB1 NM_000166.6(GJB1):c.43C>T (p.Arg15Trp)SNV Pathogenic 21084 rs116840815 X:70443600-70443600 X:71223750-71223750
31 GJB1 NM_000166.6(GJB1):c.556G>A (p.Glu186Lys)SNV Pathogenic 21086 rs116840821 X:70444113-70444113 X:71224263-71224263
32 GJB1 NM_000166.6(GJB1):c.172C>T (p.Pro58Ser)SNV Pathogenic 97063 rs483352926 X:70443729-70443729 X:71223879-71223879
33 GJB1 NM_000166.6(GJB1):c.64C>T (p.Arg22Ter)SNV Pathogenic 447441 rs1555937020 X:70443621-70443621 X:71223771-71223771
34 GJB1 NM_000166.6(GJB1):c.392_393TG[1] (p.Trp132fs)short repeat Pathogenic 521808 rs1555937168 X:70443951-70443952 X:71224099-71224100
35 GJB1 NM_000166.6(GJB1):c.281A>G (p.His94Arg)SNV Pathogenic 637565 X:70443838-70443838 X:71223988-71223988
36 GJB1 NM_000166.6(GJB1):c.466_467CT[1] (p.Tyr157fs)short repeat Pathogenic 804027 X:70444023-70444024 X:71224173-71224174
37 GJB1 NM_000166.6(GJB1):c.783_784del (p.Ile262fs)deletion Pathogenic 807420 X:70444339-70444340 X:71224489-71224490
38 GJB1 NM_000166.6(GJB1):c.65G>A (p.Arg22Gln)SNV Pathogenic/Likely pathogenic 406228 rs1060501002 X:70443622-70443622 X:71223772-71223772
39 GJB1 NM_000166.6(GJB1):c.547C>T (p.Arg183Cys)SNV Pathogenic/Likely pathogenic 216039 rs863224471 X:70444104-70444104 X:71224254-71224254
40 GJB1 NM_000166.6(GJB1):c.467T>G (p.Leu156Arg)SNV Pathogenic/Likely pathogenic 10437 rs104894818 X:70444024-70444024 X:71224174-71224174
41 GJB1 NM_000166.6(GJB1):c.536G>A (p.Cys179Tyr)SNV Likely pathogenic 21085 rs116840822 X:70444093-70444093 X:71224243-71224243
42 GJB1 NM_000166.6(GJB1):c.538T>C (p.Phe180Leu)SNV Likely pathogenic 637881 X:70444095-70444095 X:71224245-71224245
43 GJB1 NM_000166.6(GJB1):c.118G>T (p.Ala40Ser)SNV Likely pathogenic 691948 X:70443675-70443675 X:71223825-71223825
44 GJB1 NM_000166.6(GJB1):c.-16-2A>GSNV Likely pathogenic 243072 rs751230398 X:70443540-70443540 X:71223690-71223690
45 GJB1 NM_000166.6(GJB1):c.590C>T (p.Ala197Val)SNV Conflicting interpretations of pathogenicity 617760 rs1569215418 X:70444147-70444147 X:71224297-71224297
46 GJB1 NM_000166.6(GJB1):c.394T>C (p.Trp132Arg)SNV Conflicting interpretations of pathogenicity 617787 rs1569215263 X:70443951-70443951 X:71224101-71224101
47 GJB1 NM_000166.6(GJB1):c.225del (p.Leu76fs)deletion Conflicting interpretations of pathogenicity 21083 rs116840820 X:70443781-70443781 X:71223931-71223931
48 GJB1 NM_000166.6(GJB1):c.123G>C (p.Glu41Asp)SNV Conflicting interpretations of pathogenicity 21079 rs116840816 X:70443680-70443680 X:71223830-71223830
49 GJB1 NM_000166.6(GJB1):c.145T>C (p.Ser49Pro)SNV Conflicting interpretations of pathogenicity 21080 rs116840817 X:70443702-70443702 X:71223852-71223852
50 GJB1 NM_000166.6(GJB1):c.425G>A (p.Arg142Gln)SNV Conflicting interpretations of pathogenicity 188174 rs786204123 X:70443982-70443982 X:71224132-71224132
Sources

Expression for X-Linked Charcot-Marie-Tooth Disease

About this section
Search GEO for disease gene expression data for X-Linked Charcot-Marie-Tooth Disease.
Sources

Pathways for X-Linked Charcot-Marie-Tooth Disease

About this section

Pathways related to X-Linked Charcot-Marie-Tooth Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Gap junction trafficking 65
Show member pathways
 10.95 GJB2 GJB1
2
Oligomerization of connexins into connexons 65
Show member pathways
 9.58 GJB2 GJB1
Sources

GO Terms for X-Linked Charcot-Marie-Tooth Disease

About this section

Cellular components related to X-Linked Charcot-Marie-Tooth Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lateral plasma membrane GO:0016328 9.16 GJB2 GJB1
2 gap junction GO:0005921 8.96 GJB2 GJB1
3 connexin complex GO:0005922 8.62 GJB2 GJB1

Biological processes related to X-Linked Charcot-Marie-Tooth Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell communication GO:0007154 9.16 GJB2 GJB1
2 gap junction assembly GO:0016264 8.96 GJB2 GJB1
3 epididymis development GO:1905867 8.62 GJB2 GJB1

Molecular functions related to X-Linked Charcot-Marie-Tooth Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 gap junction channel activity GO:0005243 8.62 GJB2 GJB1
Sources

Sources for X-Linked Charcot-Marie-Tooth Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....